Sfoglia per AUTORE
PRATI G
Collezione AO Ordine Mauriziano

  

Items : 10

Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study. in Cancer immunology, immunotherapy : CII / Cancer Immunol Immunother. 2024 Jul 2;73(9):161. doi: 10.1007/s00262-024-03741-2.

2024
ASL Cuneo 2
AO Ordine Mauriziano

Rescigno P; Fornarini G; Buti S; Rebuzzi SE; Vignani F; Cavo A; Signori A; Banna GL; Tudini M; Malgeri A; Nole F; Prati G; Morelli F; Messina M; Di Napoli M; Atzori F; Prati V; Soraru M; Panni S; Mollica V; Pipitone S; Ricotta R; Fratino L; Catalano F; Milella M; Procopio G; Naglieri E; Masini C; Zucal PA; et alii...

Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab. in Immunotherapy / Immunotherapy. 2024 Aug 19:1-9. doi: 10.1080/1750743X.2024.2385881.

2024
ASL Cuneo 2
AO Ordine Mauriziano

Murianni V; Rescigno P; Banna GL; Fornarini G; Buti S; Nolè F; Catalano F; Prati G; Morelli F; Messina M; Atzori F; Tudini M; Prati V; Cavo A; Roviello G; Vignani F; Caffo O; Napoli MD; Malgeri A; Rebuzzi SE; Signori A; Damassi A; Cremante M;

Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study. in Frontiers in oncology / Front Oncol. 2024 Feb 12;14:1307635. doi: 10.3389/fonc.2024.1307635. eCollection 2024.

2024
ASL Cuneo 2
AO Ordine Mauriziano

Chiellino S; Galli L; Banna GL; Fornarini G; Rescigno P; Cremante M; Damassi A; Catalano F; Roviello G; Cavo A; Lipari H; Vignani F; Prati G; Spada M; Nolè F; Morelli F; Di Napoli M; Caffo O; Malgeri A; Atzori F; Prati V; Tudini M; Sorarù M; Mollica V; Ricotta R; Baldessari C; Procopio G; Milella M; Fratino L; et alii...

Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Nivolumab. in JAMA network open / JAMA Netw Open. 2023 Nov 1;6(11):e2345185. doi: 10.1001/jamanetworkopen.2023.45185.

2023
ASL Cuneo 2
AO Ordine Mauriziano

Naglieri E; Signori A; Banna GL; Rescigno P; Antonuzzo L; Roviello G; Di Napoli M; Malgeri A; Cavo A; Vignani F; Nolè F; Prati G; Atzori F; Morelli F; Caffo O; Prati V; Mollica V; Tudini M; Fratino L; Sorarù M; Ricotta R; Pipitone S; Catalano F; Chiellino S; Milella M; Procopio G; Fornarini G; Zucali PA; Buti S; et alii...

The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study. in Journal of translational medicine / J Transl Med. 2022 Sep 30;20(1):435. doi: 10.1186/s12967-022-03601-6.

2022
ASL Cuneo 2
AO Ordine Mauriziano

Roviello G; Rescigno P; Cavo A; Atzori F; Di Napoli M; Caffo O; Messina M; Morelli F; Prati G; Nolè F; Vignani F; Santini D; Cortellini A; Prati V; Soto Parra HJ; Mollica V; Sorarù M; Santoni M; Panni S; Ricotta R; Pipitone S; Fratino L; Buti S; Procopio G; Milella M; Boccardo F; Fantinel E; Naglieri E; Galli L; et alii...

The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The ?-Meet-URO analysis. in Frontiers in oncology / Front Oncol. 2022 Sep 23;12:955501. doi: 10.3389/fonc.2022.955501. eCollection 2022.

2022
ASL Cuneo 2
AO Ordine Mauriziano

Buti S; Fornarini G; Banna GL; Porta C; Llaja Obispo MA; Roviello G; Cavo A; Vignani F; Nolè F; Caffo O; Messina M; Morelli F; Prati G; Soto Parra HJ; Atzori F; Di Napoli M; Santoni M; Cortellini A; Prati V; Massari F; Sorarù M; Panni S; Fratino L; Sabbatini R; Ricotta R; Boccardo F; Milella M; Procopio G; Zucali PA; et alii...

Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). in Therapeutic advances in medical oncology / Ther Adv Med Oncol. 2021 May 18;13:17588359211019642. doi: 10.1177/17588359211019642. eCollection 20

2021
AO Ordine Mauriziano
ASL Cuneo 2

Buti S; Porta C; Perrino M; Brunelli M; Iacovelli R; Paolieri F; Chiellino S; Bersanelli M; Casadei C; Cavo A; Roviello G; Pierantoni F; Prati G; Vignani F; Nolè F; Morelli F; Messina M; Pignata S; Messina C; Stellato M; Atzori F; Soto Parra HJ; Cortellini A; Prati V; Sorarù M; Santoni M; Mollica V; Panni S; Fratino L; et alii...

Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2019 Feb;17(1):e150-e155. doi: 10.1016/j.clgc.2018.10.001. Epub 2018 Oct 10.

2019
AO Ordine Mauriziano

Masini C; Vitale MG; Maruzzo M; Procopio G; de Giorgi U; Buti S; Rossetti S; Iacovelli R; Atzori F; Cosmai L; Vignani F; Prati G; Scagliarini S; Guida A; Berselli A; Pinto C;

CORE-URO-01 study: Comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure in Annals of Oncology

2017
AO Ordine Mauriziano
ASL Cuneo 2
AOU San Luigi di Orbassano

Masini C; Vitale MG; Maruzzo M; Procopio G; De Giorgi U; Buti S; Rossetti S; Iacovelli R; Guida A; Atzori F; Mucciarini C; Cosmai L; Vignani F; Prati G; Scagliarini S; Berselli A; Pinto C; Baldari S; Annibale V; Lastoria S; Tucci M; Borsatti E; Monari F; Paganelli G; Verri E; Muto P; Panareo S; Mosca A; Storto G; et alii...

CORE-URO-01 study: Comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure in Annals of Oncology

2017
AO Ordine Mauriziano

Masini C; Vitale MG; Maruzzo M; Procopio G; De Giorgi U; Buti S; Rossetti S; Iacovelli R; Guida A; Atzori F; Mucciarini C; Scagliarini S; Vignani F; Prati G; Cosmai L; Berselli A; Pinto C;